At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
Minocycline +1 moredrug
Likely dose
Minocycline 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.
In Brief
A Phase 2 clinical trial evaluating Minocycline and Placebo for Oropharynx Cancer. Completed, enrolled 47 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOropharynx Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedAug 2010
Primary CompletionJul 2020
TodayJul 2026
First PostedAug 2, 2010
Enrollment StartJul 22, 2010
Primary CompletionJul 7, 2020
TodayJul 2, 2026
Enrollment to primary: 10.0 yearsPosted 15.9 years ago
Interventions
Minocyclinedrug
100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
Placebodrug
Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.